SEC Form 4	
------------	--

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287

	Estimated average burden	
	hours per response:	0.5
-		

	s of Reporting Person	*	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT]		tionship of Reporting Perso all applicable)	n(s) to Issuer						
MAHONEY	<u>DAVID L</u>			X	Director	10% Owner						
	(First) THERAPEUTICS	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/08/2015		Officer (give title below)	Other (specify below)						
,	WEALTH DRIVE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing (Check Applicable						
(Street) MENLO PARK	СА	94025		X	Form filed by One Report	0						
(City)	(State)	(Zip)			Person							
	ty) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											

		10.51	••••••					• • • •			sposeu o	.,					
1. Title of Security (Instr. 3)			Da	2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			Acquired (A) or (D) (Instr. 3, 4 and 5)		5) Sec Ber Ow	Amount of curities neficially ned Following ported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Tra	nsaction(s) str. 3 and 4)		(113111-4)
Common stock Table I		ıble II - [8/2015 vative Securities Acq , puts, calls, warrants							y Owne	1,169,320 ed	Ι	David L. Mahoney and Winnifred C. Ellis 1998 Family Trust			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed 4. 5. Numb Execution Date, Transaction of		ative rities ired 5 sed 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		8. Price Derivativ Security (Instr. 5)	/e derivative Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				

Explanation of Responses:

1. Represents the weighted average sale price for the entire number of shares sold. The sale prices ranged from \$5.60 to \$5.98 per share.

Remarks:

/s/ Joseph K. Belanoff, CEO of **Corcept Therapeutics** 07/09/2015 Incorporated attorney-in-fact ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.